论文部分内容阅读
目的:观察中药辅助As2O3+沙利度胺治疗骨髓增生异常综合征的临床疗效。方法:25例MDS患者,随机分成两组,治疗组14例,采用中药辅助As2O3+沙利度胺治疗,对照组11例,采用As2O3+沙利度胺治疗,疗程90天,于治疗前后行血常规、骨髓涂片检查、临床症状及输血间隔时间等评估。结果:治疗90天后两组患者的指标均较前改善,指标改善中药参与组较早出现且更明显;同时考虑患者的症状改善情况,治疗组整体疗效较对照组更为显著,有效率高达78.5%。结论:中药辅助As2O 3+沙利度胺治疗骨髓增生异常综合症90天后,较对照组更能改善患者外周血等的相关指标,同时改善患者症状,整体疗效满意。
Objective: To observe the clinical efficacy of traditional Chinese medicine-assisted As2O3 + thalidomide in the treatment of myelodysplastic syndromes. Methods: Twenty-five patients with MDS were randomly divided into two groups. The treatment group (14 cases) was treated with As2O3 + thalidomide and the control group (11 cases) treated with As2O3 + thalidomide for 90 days. Before and after treatment, blood routine , Bone marrow smear examination, clinical symptoms and blood transfusion interval evaluation. Results: After 90 days of treatment, the indexes of both groups improved compared with those of the control group, and the improvement of the indicators was earlier and more obvious in the participating groups of TCM. At the same time, taking the patients’ symptom improvement into consideration, the curative effect of the treatment group was more obvious than the control group with an effective rate as high as 78.5 %. CONCLUSION: After 90 days treatment with As2O3 + thalidomide, myelodysplastic syndromes can improve peripheral blood and other related indicators and improve the symptoms of patients. The overall efficacy is satisfactory.